Titlebook: Advances in Targeted Cancer Therapy; Paul L. Herrling,Alex Matter (Director),Richard M. Book 2005 Birkh?user Basel 2005 angiogenesis.antib

只看該作者 · 發(fā)表于 2025-3-23 19:03:47

Angiogenesis inhibitors: What is the clinical future?,s or classic chemotherapy, there is no longer doubt that anti-angiogenic agents have become part of anticancer therapy in general. In the coming years, we should further explore the treatment strategies in which anti-angiogenic agents will add to a prolonged survival and an increase in the cure rate

只看該作者 · 發(fā)表于 2025-3-23 23:24:03

只看該作者 · 發(fā)表于 2025-3-24 04:15:42

https://doi.org/10.1007/3-7643-7414-4angiogenesis; antibody; apoptosis; cancer; cancer prevention; cancer therapy; cancer treatment; cell; metast

只看該作者 · 發(fā)表于 2025-3-24 09:25:20

只看該作者 · 發(fā)表于 2025-3-24 11:23:59

Paul L. Herrling,Alex Matter (Director),Richard M.Excellent overview of new approaches for the treatment of cancer.Covers a large range of molecular targets.Discusses the potential for clinical application

只看該作者 · 發(fā)表于 2025-3-24 14:52:01

Progress in Drug Researchhttp://image.papertrans.cn/a/image/149983.jpg

只看該作者 · 發(fā)表于 2025-3-24 19:52:22

只看該作者 · 發(fā)表于 2025-3-25 00:49:41

		自動登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點評	投稿經(jīng)驗總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學	Yale Uni.	Stanford Uni.
\|Archiver\|手機版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-24 18:15
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved